291 related articles for article (PubMed ID: 24055267)
1. Gastrointestinal-related uremic toxins in peritoneal dialysis: a pilot study with a 5-year follow-up.
Lin CJ; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
Arch Med Res; 2013 Oct; 44(7):535-41. PubMed ID: 24055267
[TBL] [Abstract][Full Text] [Related]
2. The role of protein-bound uremic toxins on peripheral artery disease and vascular access failure in patients on hemodialysis.
Lin CJ; Pan CF; Liu HL; Chuang CK; Jayakumar T; Wang TJ; Chen HH; Wu CJ
Atherosclerosis; 2012 Nov; 225(1):173-9. PubMed ID: 22981405
[TBL] [Abstract][Full Text] [Related]
3. Meta-Analysis of the Associations of p-Cresyl Sulfate (PCS) and Indoxyl Sulfate (IS) with Cardiovascular Events and All-Cause Mortality in Patients with Chronic Renal Failure.
Lin CJ; Wu V; Wu PC; Wu CJ
PLoS One; 2015; 10(7):e0132589. PubMed ID: 26173073
[TBL] [Abstract][Full Text] [Related]
4. P-cresyl sulfate is a valuable predictor of clinical outcomes in pre-ESRD patients.
Lin CJ; Pan CF; Chuang CK; Sun FJ; Wang DJ; Chen HH; Liu HL; Wu CJ
Biomed Res Int; 2014; 2014():526932. PubMed ID: 24592393
[TBL] [Abstract][Full Text] [Related]
5. Increased p-cresyl sulfate level is independently associated with poor outcomes in patients with heart failure.
Wang CH; Cheng ML; Liu MH; Shiao MS; Hsu KH; Huang YY; Lin CC; Lin JF
Heart Vessels; 2016 Jul; 31(7):1100-8. PubMed ID: 26135926
[TBL] [Abstract][Full Text] [Related]
6. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function.
Viaene L; Meijers BK; Bammens B; Vanrenterghem Y; Evenepoel P
Perit Dial Int; 2014; 34(1):71-8. PubMed ID: 24179107
[TBL] [Abstract][Full Text] [Related]
7.
Chen Z; Xu J; Xing X; Xue C; Luo X; Gao S; Mao Z
Ren Fail; 2022 Dec; 44(1):1791-1800. PubMed ID: 36278836
[TBL] [Abstract][Full Text] [Related]
8. Shen-Shuai-Ning granule decreased serum concentrations of indoxyl sulphate in uremic patients undergoing peritoneal dialysis.
Chen X; Gao S; Ruan M; Chen S; Xu J; Xing X; Pan X; Mei C; Mao Z
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 29921575
[TBL] [Abstract][Full Text] [Related]
9. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease.
Lin CJ; Liu HL; Pan CF; Chuang CK; Jayakumar T; Wang TJ; Chen HH; Wu CJ
Arch Med Res; 2012 Aug; 43(6):451-6. PubMed ID: 22885091
[TBL] [Abstract][Full Text] [Related]
10. LC-MS/MS method for simultaneous determination of serum p-cresyl sulfate and indoxyl sulfate in patients undergoing peritoneal dialysis.
Shu C; Chen X; Xia T; Zhang F; Gao S; Chen W
Biomed Chromatogr; 2016 Nov; 30(11):1782-1788. PubMed ID: 27129599
[TBL] [Abstract][Full Text] [Related]
11. Indoxyl sulfate, not P-cresyl sulfate, is associated with advanced glycation end products in patients on long-term hemodialysis.
Lin CJ; Lin J; Pan CF; Chuang CK; Liu HL; Sun FJ; Wang TJ; Chen HH; Wu CJ
Kidney Blood Press Res; 2015; 40(2):121-9. PubMed ID: 25833743
[TBL] [Abstract][Full Text] [Related]
12. Uraemic toxins and cardiovascular disease across the chronic kidney disease spectrum: an observational study.
Rossi M; Campbell K; Johnson D; Stanton T; Pascoe E; Hawley C; Dimeski G; McWhinney B; Ungerer J; Isbel N
Nutr Metab Cardiovasc Dis; 2014 Sep; 24(9):1035-42. PubMed ID: 24880738
[TBL] [Abstract][Full Text] [Related]
13. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients--a prospective cohort study.
Wu IW; Hsu KH; Hsu HJ; Lee CC; Sun CY; Tsai CJ; Wu MS
Nephrol Dial Transplant; 2012 Mar; 27(3):1169-75. PubMed ID: 21891772
[TBL] [Abstract][Full Text] [Related]
14. The association of uremic toxins and inflammation in hemodialysis patients.
Hsu HJ; Yen CH; Wu IW; Hsu KH; Chen CK; Sun CY; Chou CC; Chen CY; Tsai CJ; Wu MS; Lee CC
PLoS One; 2014; 9(7):e102691. PubMed ID: 25051062
[TBL] [Abstract][Full Text] [Related]
15. High correlation between clearance of renal protein-bound uremic toxins (indoxyl sulfate and p-cresyl sulfate) and renal water-soluble toxins in peritoneal dialysis patients.
Huang WH; Hung CC; Yang CW; Huang JY
Ther Apher Dial; 2012 Aug; 16(4):361-7. PubMed ID: 22817125
[TBL] [Abstract][Full Text] [Related]
16. Differences in Dialysis Efficacy Have Limited Effects on Protein-Bound Uremic Toxins Plasma Levels over Time.
Krieter DH; Kerwagen S; Rüth M; Lemke HD; Wanner C
Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30654454
[TBL] [Abstract][Full Text] [Related]
17. Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study.
Crespo-Salgado J; Vehaskari VM; Stewart T; Ferris M; Zhang Q; Wang G; Blanchard EE; Taylor CM; Kallash M; Greenbaum LA; Aviles DH
Microbiome; 2016 Sep; 4(1):50. PubMed ID: 27640125
[TBL] [Abstract][Full Text] [Related]
18. Improved cardiovascular autonomic function and decreased protein-bound uremic toxins in patients with end-stage renal disease after peritoneal dialysis.
Cheng BC; Lai YR; Huang CC; Lu CH
J Int Med Res; 2020 Jul; 48(7):300060520933797. PubMed ID: 32692275
[TBL] [Abstract][Full Text] [Related]
19. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease.
Nazzal L; Roberts J; Singh P; Jhawar S; Matalon A; Gao Z; Holzman R; Liebes L; Blaser MJ; Lowenstein J
Nephrol Dial Transplant; 2017 Nov; 32(11):1809-1817. PubMed ID: 28379433
[TBL] [Abstract][Full Text] [Related]
20. Removal of Protein-Bound Uremic Toxins during Hemodialysis Using a Binding Competitor.
Madero M; Cano KB; Campos I; Tao X; Maheshwari V; Brown J; Cornejo B; Handelman G; Thijssen S; Kotanko P
Clin J Am Soc Nephrol; 2019 Mar; 14(3):394-402. PubMed ID: 30755453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
